The Role of Jdrf in Developing Closed-loop Systems for Elderly T1d Patients

The Vital Role of JDRF in Bringing Closed-Loop Systems to Elderly Type 1 Diabetes Patients

Type 1 diabetes (T1D) is a lifelong autoimmune condition that demands constant vigilance over blood glucose levels. For elderly individuals living with T1D, the burden of daily management is compounded by age-related physiological changes, cognitive decline, and a higher risk of dangerous hypoglycemia. The Juvenile Diabetes Research Foundation (JDRF) has long championed technological breakthroughs in diabetes care, and its focus on closed-loop systems—often called an artificial pancreas—represents one of the most promising frontiers. This article examines how JDRF’s research funding, policy advocacy, and collaboration with industry leaders are accelerating the development of closed-loop technology specifically tailored for the needs of older adults, enhancing safety, independence, and quality of life.

Understanding Closed-Loop Systems: How They Work and Why They Matter

A closed-loop system is an integrated automated insulin delivery (AID) platform that links a continuous glucose monitor (CGM), an insulin pump, and a control algorithm. Unlike traditional “open-loop” therapy where patients must manually calculate and deliver insulin doses, a closed-loop system continuously reads glucose levels from the CGM, predicts trends, and automatically adjusts the pump’s insulin infusion rate to keep glucose within a target range. The algorithm—housed in a smartphone app, a dedicated controller, or directly in the pump—is the brain of the operation, learning the user’s patterns over time.

There are two main categories of closed-loop systems:

Hybrid closed-loop systems: These automate basal insulin delivery but still require the user to manually bolus for meals. They have been the first to reach the market and are widely used today (e.g., Medtronic MiniMed 670G/780G, Tandem t:slim X2 with Control-IQ).
Fully closed-loop systems: These aim to handle both basal and meal-time insulin delivery automatically, with minimal or no user input. Fully automated systems are still under development but have shown promising results in clinical trials.

For elderly patients, the primary benefits of any closed-loop system are two-fold: reducing the likelihood of both hyperglycemia and severe hypoglycemia and lightening the mental load of constant decision-making. Research has shown that older adults with T1D spend a significant portion of their day in hypoglycemia, which can lead to falls, hospitalizations, and cognitive impairment. Closed-loop systems offer a layer of protection that manual therapy cannot match.

The Unique Challenges Elderly T1D Patients Face

Increased Risk of Hypoglycemia

Age-related changes in counter-regulatory hormone responses (especially reduced glucagon and epinephrine release) make older adults more vulnerable to hypoglycemia. Kidney function decline can prolong insulin action, and polypharmacy—common among seniors—may mask or worsen hypoglycemic symptoms. A single severe hypoglycemic event can have devastating consequences, including cardiac arrhythmia or traumatic injury from a fall.

Cognitive and Physical Limitations

Mild cognitive impairment or early dementia makes it challenging to manage multiple daily insulin injections, count carbohydrates, and interpret CGM trends. Arthritis, vision loss, and fine-motor difficulties can further impede tasks like drawing up insulin or pressing buttons on a pump. Closed-loop systems reduce the number of manual actions required: once set up, the device automates most adjustments, relying on the algorithm rather than the user’s cognitive speed or dexterity.

Many elderly T1D patients live alone or have limited caregiver support. Fear of hypoglycemia can restrict physical activity, social outings, and even driving—eroding independence and mental health. A reliable closed-loop system can restore confidence, allowing seniors to engage more fully in daily life without constant worry about their blood sugar.

JDRF’s Strategic Investment in Elderly-Focused Technology

JDRF has been instrumental in accelerating closed-loop development through its Artificial Pancreas Project (APP), launched in 2006. The foundation funds pivotal clinical trials, partners with device manufacturers, and works with regulatory bodies like the U.S. Food and Drug Administration (FDA) to streamline approval pathways. Crucially, JDRF recognizes that technology designed for younger, tech-savvy users may not meet the needs of older adults.

Funding Dedicated Trials for Seniors

One landmark study supported by JDRF was the “Closed-loop in Older Adults” trial conducted at the University of Virginia Center for Diabetes Technology. This clinical trial compared hybrid closed-loop therapy with sensor-augmented pump therapy in adults aged 60 and older. Results, published in Diabetes Care, showed that closed-loop therapy significantly reduced time below 70 mg/dL (hypoglycemia) and improved time-in-range without increasing severe hyperglycemia. JDRF’s funding made such age-specific research possible, generating evidence that regulators and payers use to approve and reimburse these systems.

Collaboration with Technology Partners

JDRF works closely with companies like Tandem Diabetes Care, Insulet, Medtronic, and Dexcom to design features for older users. For example, JDRF advocated for larger, high-contrast displays, simplified menu navigation, and audible alarms instead of only vibrating alerts. Some systems now offer a “senior-friendly mode” that reduces the number of notifications and allows a caregiver or family member to remotely monitor glucose data via a smartphone app.

Policy and Advocacy Work

Beyond research, JDRF lobbies for Medicare and private insurance coverage of closed-loop technology. The foundation played a key role in the Medicare National Coverage Determination (NCD) for CGMs and insulin pumps, and it continues to push for coverage of AID systems without age-based restrictions. In 2023, JDRF submitted formal comments advocating for streamlined eligibility criteria that do not require a history of severe hypoglycemia—a requirement that disproportionately excludes elderly patients who may not report events.

Key Clinical Trials and Outcomes for Elderly Users

Trial/Study	Population	Key Finding
UVA Closed-loop in Older Adults (JDRF-funded)	60+ years, T1D	Reduction in hypoglycemia by 48%, improved time-in-range by 12%
DCLP3 (APCam) Study	Mixed ages (subset 65+)	Closed-loop safe and effective in older subgroup; high user satisfaction
Insulin-only iLet Bionic Pancreas Trial	Adults with T1D (included >65)	Similar glycemic improvements regardless of age; simpler setup for those with limited tech experience

These studies consistently demonstrate that closed-loop systems are not only safe for elderly patients but often deliver superior outcomes compared to standard therapy. A 2022 meta-analysis of hybrid closed-loop trials found that older adults had the greatest absolute reduction in hypoglycemia, likely because their baseline risk was highest.

Addressing User-Friendliness and Accessibility

Simplifying the User Interface

One barrier to adoption is the complexity of current closed-loop systems. Many require daily calibration, frequent sensor changes, and manual entry of meal carbohydrates. JDRF has highlighted the need for “low-proxy” systems where the user does not need to enter carb counts at all. The iLet bionic pancreas (being developed by Beta Bionics in collaboration with JDRF) uses an initial weight-based dosing strategy and only requires the user to provide a rough estimate of meal size (small, medium, large) instead of grams of carbohydrate. This significantly reduces cognitive demand for elderly users.

Training and Support

JDRF funds educational programs specifically for older adults and their caregivers. The foundation’s Type1Nation chapters often host workshops where seniors can practice with devices under the guidance of a diabetes educator. Additionally, JDRF advocates for reimbursement of ongoing training and help-line support so that elderly users can get troubleshooting assistance without needing to visit a clinic.

Integration with Remote Monitoring

For elderly patients who live alone, the ability to share CGM data with a family member or healthcare provider is crucial. JDRF supports development of systems that automatically notify a caregiver if glucose falls below a threshold or if the pump delivers an unusually low amount of insulin. Platforms like Tidepool, Dexcom’s Follow app, and Tandem’s t:connect are now integrated into many closed-loop systems, and JDRF has urged manufacturers to make these features standard rather than optional.

Hybrid vs. Fully Automated Systems: Which Is Better for Seniors?

Currently, only hybrid closed-loop systems are commercially available. While they reduce workload dramatically, they still require the user to bolus for meals. For elderly patients with irregular meal patterns, memory issues, or those who skip meals, this can be a stumbling block. Fully automated systems that handle meal detection autonomously—sometimes called “closed-loop with unannounced meals”—are under investigation.

JDRF is funding research into meal detection algorithms that use CGM data alone to recognize when a user is eating, without requiring a manual announcement. Early results from studies at the University of Cambridge and the University of Virginia show that such systems can maintain glucose control without user input, though they may cause larger post-prandial spikes. The goal is to find the optimal balance between automation and safety, especially for seniors who may forget to bolus.

For the near future, hybrid systems remain the gold standard. However, JDRF’s investment in next-generation algorithms promises that fully automated systems will eventually become available—potentially within the next five years—for those who need the highest level of support.

Real-World Impact: Stories from Elderly Users

“I was afraid of going low at night for years. I’d set alarms to wake up and check my sugar. Since I started using a hybrid closed-loop pump, my blood sugar stays stable all night. I finally get a good night’s sleep, and my daughter doesn’t have to call me every morning to make sure I’m okay.”
— Margaret, 72, living with T1D for 40 years

Such testimonials are not outliers. In a satisfaction survey of older adults using closed-loop therapy, 89% reported that the device reduced their fear of hypoglycemia, and 78% said it allowed them to participate in more physical activities like walking or gardening. The emotional relief is often as valuable as the clinical improvement.

Looking Ahead: Future Directions in Closed-Loop Technology for Seniors

Dual-Hormone Systems

JDRF is also supporting development of dual-hormone closed-loop systems that deliver both insulin and glucagon (or pramlintide). For elderly patients, the addition of glucagon can rescue from severe hypoglycemia without requiring external intervention. Early pilot studies have shown that dual-hormone systems can virtually eliminate hypoglycemia for extended periods.

Artificial Intelligence and Predictive Alerts

Machine learning algorithms that can predict hypoglycemia hours in advance are being integrated into closed-loop controllers. JDRF funds the Big Data in Diabetes Initiative, which analyzes glucose patterns from thousands of users to refine predictive models. For seniors, a system that can warn them to eat a snack before exercise or before bed could be life-saving.

Addressing Cost and Accessibility

The high cost of closed-loop systems remains a barrier for many elderly patients on fixed incomes. JDRF works with manufacturers to negotiate lower prices and with government agencies to expand coverage. The foundation has also supported the development of open-source automated insulin delivery systems (e.g., Loop, OpenAPS), though these require significant technical expertise and are not recommended for seniors without caregiver support. JDRF continues to advocate for a regulatory pathway that would allow safe, low-cost, commercial versions of these systems to be approved.

Conclusion: JDRF’s Ongoing Commitment to Elderly T1D Patients

The development of closed-loop systems for Type 1 diabetes has moved from science fiction to clinical reality. JDRF’s strategic investments, advocacy, and partnerships have been central to this progress. By focusing on the unique needs of elderly patients—who face the highest risk of complications but also stand to gain the most from automation—JDRF ensures that technological advances do not leave the most vulnerable behind. As closed-loop technology continues to mature, it will offer older adults with T1D a path toward greater safety, independence, and peace of mind.

For more information about JDRF’s closed-loop initiatives and clinical trials for seniors, visit JDRF’s official website. To read the latest clinical study on closed-loop therapy in older adults, see the full publication in Diabetes Care. For details on the iLet bionic pancreas and its user-friendly design, visit Beta Bionics. To view current FDA-approved hybrid closed-loop systems, refer to the FDA Artificial Pancreas Device Database. JDRF also provides caregiver resources and support groups through its T1D Resources page.